UNICREDIT BANK/CALL/ELI LILLY & CO/700/0.1/18.12.24 | Market Closed - BOERSE MUENCHEN 15:41:59 2024-05-31 EDT | ||
| 14.51 EUR | -0.27% |
|
| 1 month | +16.64% | ||
| 3 months | +22.45% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 14.51 | -0.27% |
| 24-05-30 | 14.55 | +1.25% |
| 24-05-29 | 14.37 | +4.51% |
| 24-05-28 | 13.75 | -4.91% |
| 24-05-27 | 14.46 | +1.54% |
Real-time BOERSE MUENCHEN
Last update May 31, 2024 at 03:41 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
UniCredit
|
| WKN | HC7N7B |
| ISIN | DE000HC7N7B6 |
| Date issued | 2023-06-23 |
| Strike | 700 $ |
| Maturity | 2024-12-18 (199 Days) |
| Parity | 10 : 1 |
| Emission price | 1.18 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 14.8 € |
|---|---|
| Lowest since issue | 0.58 € |
| Spread | 0.06 € |
| Spread % | 0.40% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
820.3
USD
Average target price
852.5
USD
Spread / Average Target
+3.92%
- Stock Market
- Warrants
- Warrant
